Latest Articles and Analysis

Q4 2024 Watch: HCV treatment access assessment with guidance for disaster-displaced individuals.

Elevated HCV prevalence among HIV-positive MSM and co-infection management implications.

Innovative approaches to improve HIV care transitions for people exiting incarceration.

Systemic barriers preventing HCV-infected people from accessing available cure.

Q3 2024 Watch monitoring HCV treatment access across ADAPs, Medicaid, Veterans programs, and assistance initiatives.

HCV co-infection in HIV-positive MSM: treatment barriers through ADAPs and policy recommendations.

ADAP coverage gaps for long-acting injectable HIV treatments and equity implications.

Barriers to HIV care for formerly incarcerated people and continuity strategies.

Declining HCV infections but persistent treatment barriers and disparities remain.

WHO updated hepatitis B guidelines: implications for global HBV testing and treatment.

Major HIV research breakthroughs from CROI 2024: long-acting treatments and prevention advances.

Australian study: 1% viral load suppression increase correlates with 6% decrease in HIV diagnoses.

Louisiana and Washington HCV subscription models save millions but fail elimination goals; cost alone isn't the barrier.

European Commission approves lenacapavir, a novel six-month injectable for treatment-resistant HIV.

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

85,000+ fake HIV medication bottles distributed through counterfeiting rings endanger patient safety.

ADAP Advocacy Association Fireside Chats resume with discussions on utilization management and EHE progress.